The text starts here.

News Release

August 22, 1997

Eisai Establishes KAN Research Institute

Tokyo (August 22,1997) - Eisai Co., Ltd. of Tokyo (President and CEO: Haruo Naito) today announced the start of operations of the KAN Research Institute, a 100 percent Eisai subsidiary, focusing on life science exploratory research.*

Progress in molecular and cell biology has brought about an increase in the understanding of the mechanisms of undefined disease action.

The principal research will be conducted utilizing the most advanced life science technology with the objective of developing new drugs for the benefit of patients suffering from severe and incurable diseases.

Company Outline

• Company Name: KAN Research Institute,Inc.
• Location: Osaka,Japan
• President: Masanori Komatsu
• Employees: 10
• Capital: yen20,000,000
• Establishment: April 25,1997

*Note: In the pharmaceutical field, life science research attempts to discover the mechanism of undefined disease action, including autoimmune diseases, based on molecular and cell biology. Within the pharmaceutical industry, this is an important development in new drug research.

Eisai Co., a research-based human health care company which discovers, develops and markets products in more than 30 countries. Through its global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of worldwide health care systems.The Company reported sales of $2.3 billion in 1996 with approximately 14 percent of sales spent on research and development.